Clinical implications of interleukins-31, 32, and 33 in gastric cancer

Table 1 Correlations between interleukin-31, interleukin-32, and interleukin-33 expression and clinical/pathological features in patients with gastric cancer (n = 180)

Characteristic	Patient number	IL-31 median	P value	IL-32 median	P value	IL-33 median	P value
All cancer	180	1.333 × 106		99245		125998
Noncancer (non)	159	1.472 × 106	0.043	138164	0.001	173818	< 0.0001
Gender
Male	140	1.344 × 106		106075		143830
Female	40	1.208 × 106	0.329	81009	0.040	89697	0.029
Age
≤ 60	79	1.082 × 106		74098		106857
> 60	101	1.404 × 106	0.007	122682	0.001	148615	0.026
Tumour size (diameter)
< 5 cm	87	1.325 × 106		98583		122572
≥ 5 cm	93	1.335 × 106	> 0.999	101583	> 0.999	126415	> 0.999
Lymph node metastasis
No	75	1.404 × 106		106075		143359
Yes	105	1.267 × 106	0.284	93196	0.671	113657	0.3
Differentiation
High	14	1.609 × 106	H/M > 1	114379	H/M > 1	171038	H/M: > 0.999
Moderate	78	1.393 × 106	H/L: 0.6	113024	H/L> 1	142850	H/L: 0.2
Low	88	1.146 × 106	M/L: 0.3	91551	M/L: 0.4	104570	M/L: 0.1
Invasion depth
T1	4	2.072 × 106		218529	T1/T3: 0.5, T1/T4: 0.6	156096
T2	27	1.600 × 106		110353		143582
T3	75	1.208 × 106		98367		116081
T4	74	1.318 × 106	All > 1	96542	T1/T2, T2/T3, T2/T4, T3/T4, all > 1	125941	All > 1
TNM
I	12	1.355 × 106		98583		142117	I/IV: 0.8
II	70	1.414 × 106		113560	II/ IV: 0.6	147031	II/III: 0.3, II/IV: 0.1
III	92	1.288 × 106		87667		107919	III/IV: 0.7
IV	6	0.950 × 106	All > 1	54851	I/II, I/III, I/IV, II/ III, III/IV, all > 1	52195	I/II, I/III>1

IL: Interleukin.